Medicus Pharma Ltd. director Patrick J. Mahaffy reported receiving a stock option grant for 50,000 underlying common shares. The option carries an exercise price of $0.36 per share, was granted on June 3, 2026, and is scheduled to vest quarterly in four equal installments over one year. The option expires on June 3, 2031, and represents a compensation-related award rather than an open-market share purchase or sale.
Medicus Pharma Ltd. director Larry Kaiser received a grant of stock options, giving him the right to acquire 50,000 common shares. The options have an exercise price of $0.36 per share and expire on June 3, 2031. Following this grant, he holds stock options for 50,000 shares. According to the grant terms, the options vest quarterly in four equal installments over one year, meaning the award becomes exercisable gradually rather than all at once.
Medicus Pharma Ltd. director Barry Fishman received a grant of stock options representing 50,000 common shares. The options have an exercise price of $0.36 per share and expire on June 3, 2031. They were granted on June 3, 2026 and are scheduled to vest quarterly in four equal installments over one year. Following this grant, Fishman holds 50,000 derivative securities directly.
Medicus Pharma Ltd. director Robert J. Ciaruffoli received a grant of stock options covering 50,000 common shares. The options have an exercise price of $0.36 per share, were granted on June 3, 2026, and are scheduled to vest quarterly in four equal installments over one year.
These options expire on June 3, 2031, and represent 50,000 derivative securities held by Ciaruffoli following this compensation-related award. The filing reports no open-market purchases or sales of Medicus Pharma common shares.
Medicus Pharma Ltd. reported that Chief Scientific Officer Brennan Edward J. received a grant of stock options. The award covers 25,000 options for Common Shares at an exercise price of $0.36 per share. According to the footnote, the options vest quarterly in four equal installments over one year and expire on June 3, 2031.
Medicus Pharma Ltd. President and CFO Carolyn F. Bonner received a compensation-related stock option grant covering 250,000 common shares. The option has an exercise price of $0.36 per share and expires on June 3, 2031.
According to the footnote, the award was granted on June 3, 2026 and is scheduled to vest quarterly in four equal installments over one year. Following this grant, Bonner holds stock options for 250,000 underlying common shares directly. This is an equity incentive grant rather than an open-market purchase.
Medicus Pharma Ltd. reported that Chief Executive Officer Raza Bokhari received a grant of stock options covering 500,000 underlying common shares. The options have an exercise price of $0.36 per share and were granted as a compensation-related award, not an open-market purchase.
According to the disclosure, the options were granted on June 3, 2026 and are scheduled to vest quarterly in four equal installments over one year, providing staged earning of the award. Following this grant, Bokhari holds 500,000 stock options directly, which are scheduled to expire on June 3, 2031 if not exercised.
Medicus Pharma Ltd. director Ashton William received a grant of stock options as part of his compensation. He was awarded options covering 50,000 common shares at an exercise price of $0.3600 per share. The options were granted on June 3, 2026 and are scheduled to vest quarterly in four equal installments over one year, ending on June 3, 2027. These options expire on June 3, 2031, and following this grant he holds options on 50,000 shares directly.
Medicus Pharma Ltd. entered into a secured note financing totaling $12,864,225 and $10,000,000 and disclosed noncompliance with Nasdaq’s market value listing standard.
The company issued a Secured Promissory Note A-1 with an 8.75% interest rate, an original issue discount of $834,225, and received $12,000,000 in cash with about $2,500,000 used to repay an existing debenture. A separate B Note of $10,000,000 at 5% interest was funded into a controlled deposit account and can be exchanged into A-type notes, releasing cash as redemptions occur. Both notes mature in 18 months and carry prepayment premiums of 110% or 115%, monthly and trading-based redemption features, and event-driven balance step-ups.
Nasdaq notified the company that its Market Value of Listed Securities has been below $35,000,000 for 30 consecutive business days and that it also fails alternative equity and income standards. Medicus has 180 days, until November 16, 2026, to regain compliance or face potential delisting, though its shares and warrants continue trading under “MDCX” and “MDCXW.”
Medicus Pharma Ltd. reports first-quarter 2026 results, with a net loss of $9.0M and no revenue as it advances its drug pipeline. Operating expenses rose sharply, driven by higher general and administrative spending and increased research and development, including work on Teverelix and SkinJect.
Cash and cash equivalents were $6.4M as of March 31, 2026, after using $9.0M in operating cash during the quarter and raising equity through a standby equity purchase agreement and at-the-market sales. Management discloses substantial doubt about the company’s ability to continue as a going concern.
The company expanded its at-the-market program and continued to rely on Yorkville-financed debentures and equity facilities, while also reporting positive Phase 2 data for its SkinJect microneedle therapy and FDA clearance to begin a Phase 2b study of Teverelix in advanced prostate cancer.